Literature DB >> 1791239

Clinical evaluation of cutaneous malignant melanoma with histologically involved lymph node metastases.

T Sugihara1, T Yoshida, T Ohura, A Ohkawara, M Kumakiri.   

Abstract

Thirty-six cases of cutaneous malignant melanoma with histologically involved lymph nodes were studied during a 2-10 year study period, and the characteristics of the metastasized nodes and the associated prognosis were compared. The results were as follows: 1) the survival rate in cases with 3 or fewer (n = 16) metastasized nodes was significantly higher than in cases with 4 or more positive nodes (n = 20); 2) the survival rate in cases in which metastasized nodes were limited to one regional lymph node section (n = 12) was significantly higher than in cases where metastasis extended to two or more intra-regional sections of nodes (n = 24); 3) cases which had nodes measuring 3.00 cm or less (n = 25) had significantly higher survival rates than those with nodes of 3.01 cm or more (n = 11). Therefore, the results indicate that the number of metastasized lymph nodes, the extension into regional lymph node sections, and the size of the metastasized lymph node(s) can be considered as important prognostic factors for melanoma patients.

Entities:  

Mesh:

Year:  1991        PMID: 1791239     DOI: 10.1111/j.1346-8138.1991.tb03138.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  2 in total

Review 1.  Treatment strategy for cutaneous malignant melanoma.

Authors:  Arata Tsutsumida; Hiroshi Furukawa; Yuhei Yamamoto; Tsuneki Sugihara
Journal:  Int J Clin Oncol       Date:  2005-10       Impact factor: 3.402

2.  Sentinel node biopsy versus elective lymph node dissection in patients with cutaneous melanoma in a Japanese population.

Authors:  Arata Tsutsumida; Hiroshi Furukawa; Yuhei Yamamoto; Katsumi Horiuchi; Tetsunori Yoshida; Hidehiko Minakawa; Satoru Fujii; Naoki Murao; Hiroaki Kuwahara; Toshiyuki Minamimoto; Hirotaka Fujioka; Taisuke Sakamoto; Toyohiro Honma
Journal:  Int J Clin Oncol       Date:  2007-08-20       Impact factor: 3.402

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.